At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Jul 30, 2026 at 16:05 ET
Myriad Genetics reported Q2 2026 revenue of $190.7M (11% YoY decline, 7.4% below consensus) and adjusted EPS of -$0.25 (vs consensus -$0.06, a 317% miss). The company lowered full-year 2026 revenue guidance to $770-790M and suspended Adjusted EBITDA guidance, citing payer friction, Prenatal Health volume declines, and a $11M revenue reduction from prior-period collection estimate changes.
- Q2 2026 revenue $190.7M vs consensus $206.0M (-7.4% miss) and vs $213.1M YoY (-11%)
- Adjusted EPS -$0.25 vs consensus -$0.06 (-316.7% miss); GAAP EPS -$0.46
- Full-year 2026 revenue guidance lowered to $770-790M (from undisclosed prior range); Adjusted EBITDA guidance suspended
- Prenatal Health revenue fell 16% YoY on 9% volume decline; Cancer Care Continuum revenue down 11% YoY despite 6% volume growth
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access